Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.11.2649 on October 29 2007

Journal of Clinical Oncology, Vol 25, No 34 (December 1), 2007: pp. 5448-5457
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Austen, B.
Right arrow Articles by Stankovic, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Austen, B.
Right arrow Articles by Stankovic, T.

Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion

Belinda Austen, Anna Skowronska, Claire Baker, Judith E. Powell, Anne Gardiner, David Oscier, Aneela Majid, Martin Dyer, Reiner Siebert, A. Malcolm Taylor, Paul A. Moss, Tatjana Stankovic

From the Cancer Research UK Institute for Cancer Studies, University of Birmingham; Department of Epidemiology and Public Health, University of Birmingham, Birmingham; Haematology Department, Royal Bournemouth Hospital, Bournemouth; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; and Institute for Human Genetics, University Hospital Schleswig-Holstein, Kiel, Germany

Address reprint requests to Tatjana Stankovic, CRUK Institute for Cancer Studies, Vincent Dr, University of Birmingham, Birmingham B15 2TT, United Kingdom; e-mail: t.stankovic{at}bham.ac.uk

Purpose: The ataxia telangiectasia mutated (ATM) gene is located on chromosome 11q and loss of this region is common in B-cell chronic lymphocytic leukemia (CLL). Our aim was to determine if CLL tumors with a chromosome 11q deletion might be divided into two subgroups based on the status of the remaining ATM allele.

Methods: The sequence of the residual ATM allele was determined in 72 CLLs with an 11q deletion. This was related to the cellular response to irradiation or cytotoxic drug exposure in vitro and clinical outcome.

Results: We show that the residual ATM allele is mutated in 36% of CLLs with an 11q deletion and that these leukemias demonstrate an impaired cellular response to irradiation or cytotoxic drug exposure in vitro. Inactivation of the second ATM allele was associated with a reduction in patient survival beyond that already dictated by the presence of an 11q deletion (P = .0283). Furthermore, we demonstrate that ATM mutations may arise during the evolution of an 11q deleted subclone and are associated with its expansion.

Conclusion: CLL with 11q deletion can be divided into two subgroups based on the integrity of the residual ATM allele. Patients with complete loss of ATM function, due to biallelic ATM defects, have defective responses to cytotoxic chemotherapeutics in vitro and a poorer clinical outcome. ATM mutant subclones can develop during an individual's disease course and give rise to additional expansion of the 11q deleted subclone.

published online ahead of print at www.jco.org on October 29, 2007.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
BloodHome page
L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Blood, September 1, 2008; 112(5): 1993 - 2003.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. Bea and E. Campo
Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior
Haematologica, May 1, 2008; 93(5): 641 - 645.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online